Company intelligence / Profile preview

Galpharma

Takamatsu, Kagawa, Japan

Ownership: Private
Development stage: Other

Overview

GalPharma is a Japanese biotechnology company specializing in the research and development of therapeutics targeting Galectin-9. Founded on the research of Dr. Mitsuomi Hirashima, the company focuses on the role of galectins in immune regulation, particularly their ability to modulate T-cell responses. GalPharma's pipeline includes monoclonal antibodies designed to treat various cancers and autoimmune conditions by targeting the Galectin-9 pathway. Additionally, the company explores the potential of Galectin-9 as a biomarker and therapeutic target for chronic viral infections such as HIV and HBV.

Therapeutic areas: ImmunologyInfectious DiseasesOncology
Modalities: Monoclonal antibodyBiologicSmall molecule
Industry: Biotech

Partnerships

Kagawa University

Beyond the preview

Go deeper on Galpharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galpharma.

Explore the full profile